Cargando…

Neurologic and psychiatric features of impending neurodegeneration in iRBD

INTRODUCTION: Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is linked to Parkinson’s disease and other alpha-synucleinopathies, but various subsets of iRBD may not carry equal risk (i.e., those with depression are at higher risk than those without). Here, we prospectively focus...

Descripción completa

Detalles Bibliográficos
Autores principales: Barone, Daniel A., Sarva, Harini, Hellmers, Natalie, Wang, Fei, Wu, Zhenxing, Krieger, Ana C., Henchcliffe, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480303/
https://www.ncbi.nlm.nih.gov/pubmed/37680305
http://dx.doi.org/10.1016/j.prdoa.2023.100216
_version_ 1785101765595627520
author Barone, Daniel A.
Sarva, Harini
Hellmers, Natalie
Wang, Fei
Wu, Zhenxing
Krieger, Ana C.
Henchcliffe, Claire
author_facet Barone, Daniel A.
Sarva, Harini
Hellmers, Natalie
Wang, Fei
Wu, Zhenxing
Krieger, Ana C.
Henchcliffe, Claire
author_sort Barone, Daniel A.
collection PubMed
description INTRODUCTION: Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is linked to Parkinson’s disease and other alpha-synucleinopathies, but various subsets of iRBD may not carry equal risk (i.e., those with depression are at higher risk than those without). Here, we prospectively focus on neurologic and psychiatric aspects of subjects with iRBD, in an attempt to determine what factors are prominent in those who undergo phenoconversion as opposed to those who do not. METHODS: We analyzed data from the “REM Sleep Behavior Disorder Associations with Parkinson’s Disease Study (RAPiDS)” cohort both at baseline and then at follow-up evaluations (1 to 3 years later) utilizing several neurologic batteries, including the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), the Montreal Cognitive Assessment (MoCA), the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP), the 10-M Walk Test (10MWT), and the Epworth Sleepiness Scale. Determination of phenoconversion was ascertained from physical examination and medical chart review from the initial evaluation onward. RESULTS: Of those who completed both evaluations, there were 33 subjects with iRBD, with an average age of 63.1 ± 12.8 years, with 9 women and 24 men. Of these, 8 (24%) iRBD subjects developed neurodegenerative illness, and demonstrated multiple areas of neurologic and psychiatric signs and symptoms, such as speech and movement problems as well as anxiety and depression. CONCLUSIONS: Our data adds to the literature regarding risk of phenoconversion in those with iRBD. Further study will be needed, but it is clear that not all subjects with iRBD present the same risk for neurodegeneration.
format Online
Article
Text
id pubmed-10480303
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104803032023-09-07 Neurologic and psychiatric features of impending neurodegeneration in iRBD Barone, Daniel A. Sarva, Harini Hellmers, Natalie Wang, Fei Wu, Zhenxing Krieger, Ana C. Henchcliffe, Claire Clin Park Relat Disord Original Articles INTRODUCTION: Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is linked to Parkinson’s disease and other alpha-synucleinopathies, but various subsets of iRBD may not carry equal risk (i.e., those with depression are at higher risk than those without). Here, we prospectively focus on neurologic and psychiatric aspects of subjects with iRBD, in an attempt to determine what factors are prominent in those who undergo phenoconversion as opposed to those who do not. METHODS: We analyzed data from the “REM Sleep Behavior Disorder Associations with Parkinson’s Disease Study (RAPiDS)” cohort both at baseline and then at follow-up evaluations (1 to 3 years later) utilizing several neurologic batteries, including the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), the Montreal Cognitive Assessment (MoCA), the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP), the 10-M Walk Test (10MWT), and the Epworth Sleepiness Scale. Determination of phenoconversion was ascertained from physical examination and medical chart review from the initial evaluation onward. RESULTS: Of those who completed both evaluations, there were 33 subjects with iRBD, with an average age of 63.1 ± 12.8 years, with 9 women and 24 men. Of these, 8 (24%) iRBD subjects developed neurodegenerative illness, and demonstrated multiple areas of neurologic and psychiatric signs and symptoms, such as speech and movement problems as well as anxiety and depression. CONCLUSIONS: Our data adds to the literature regarding risk of phenoconversion in those with iRBD. Further study will be needed, but it is clear that not all subjects with iRBD present the same risk for neurodegeneration. Elsevier 2023-08-25 /pmc/articles/PMC10480303/ /pubmed/37680305 http://dx.doi.org/10.1016/j.prdoa.2023.100216 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Articles
Barone, Daniel A.
Sarva, Harini
Hellmers, Natalie
Wang, Fei
Wu, Zhenxing
Krieger, Ana C.
Henchcliffe, Claire
Neurologic and psychiatric features of impending neurodegeneration in iRBD
title Neurologic and psychiatric features of impending neurodegeneration in iRBD
title_full Neurologic and psychiatric features of impending neurodegeneration in iRBD
title_fullStr Neurologic and psychiatric features of impending neurodegeneration in iRBD
title_full_unstemmed Neurologic and psychiatric features of impending neurodegeneration in iRBD
title_short Neurologic and psychiatric features of impending neurodegeneration in iRBD
title_sort neurologic and psychiatric features of impending neurodegeneration in irbd
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480303/
https://www.ncbi.nlm.nih.gov/pubmed/37680305
http://dx.doi.org/10.1016/j.prdoa.2023.100216
work_keys_str_mv AT baronedaniela neurologicandpsychiatricfeaturesofimpendingneurodegenerationinirbd
AT sarvaharini neurologicandpsychiatricfeaturesofimpendingneurodegenerationinirbd
AT hellmersnatalie neurologicandpsychiatricfeaturesofimpendingneurodegenerationinirbd
AT wangfei neurologicandpsychiatricfeaturesofimpendingneurodegenerationinirbd
AT wuzhenxing neurologicandpsychiatricfeaturesofimpendingneurodegenerationinirbd
AT kriegeranac neurologicandpsychiatricfeaturesofimpendingneurodegenerationinirbd
AT henchcliffeclaire neurologicandpsychiatricfeaturesofimpendingneurodegenerationinirbd